Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Standard BioTools Inc.NASDAQ: LAB

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital grows, but more slowly than its trailing trend

Q1 FY2026 change in working capital of $54.95M (cash outflow) rose 252.3% year over year, behind the +302.5% change in trailing-twelve-month change in working capital. Sequentially, it rose 77.6% from the prior quarter. Over 3 fiscal years it compounded at +53.8% a year.

Context

  • Change in working capital amounted to 52.7% of revenue in FY2025, up 45.8 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +252.3% toward the trailing-twelve-month pace of +302.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$54.95M+77.6% QoQ
Last fiscal yearDec 2025
-$44.98M+272.4% YoY
LTMMar 2026
-$87.08M+302.5% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+252.3%——
1 year+272.4%——
3-year CAGR+53.8%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(44.98M) USD
Year-over-year change
-272.4%

Change in Working Capital vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +302.5% is the 2nd highest of 10, against a peer median of +125.5%.
  • Change in working capital amounts to 101.0% of revenue for LAB, versus a peer median of 1.7%.
LAB Competitors
Change in Working Capital for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LABStandard BioTools Inc.LTM Mar 2026$87.08M USD+302.5%+53.8%101.0%
VREXVarex Imaging CorporationLTM Apr 2026$73.4M USD+24366.7%-29.1%8.6%
AVNSAvanos Medical, Inc.LTM Mar 2026$26.3M USD-142.1%—3.7%
SYSo-Young International Inc.LTM Dec 2025CN¥26.11M CNY—-48.8%1.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$12.58M USD+237.9%+8.0%—
KIDSOrthoPediatrics Corp.LTM Mar 2026$10.1M USD-310.9%-15.3%4.2%
BVSBioventus Inc.LTM Mar 2026$7.19M USD+125.5%-22.5%1.2%
ADCTADC Therapeutics S.A.LTM Mar 2026$5.08M USD+126.1%-19.7%6.4%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$1.56M USD-91.9%+13.9%0.8%
CTKBCytek Biosciences, Inc.LTM Mar 2026$1.18M USD+127.2%-50.7%0.6%
CBLLCeriBell, Inc.LTM Mar 2026$958K USD-60.2%—1.0%
Peer median (excluding LAB) —+125.5%-21.1%1.7%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Depreciation & Amortization16.2M15.03M15.18M16.86M1.72M
Deferred Income Tax00000
Stock-Based Compensation16.1M14.88M13.12M31.73M29.61M
Change in Working Capital(18.01M)(12.35M)1.79M(12.08M)(44.98M)
Accounts Receivables6.73M1.06M(2.99M)8.97M(1.36M)
Inventory(4.78M)(8.47M)(4.91M)(9.88M)(11.52M)
Accounts Payables001.62M02.44M
Other Working Capital(19.95M)(4.95M)8.07M(11.17M)(34.53M)
Other Non-Cash Items886K83.17M1.28M(41.08M)14.2M
Operating Cash Flow(44.06M)(89.37M)(43.29M)(143.45M)(74.35M)
Capital Expenditures(13.26M)(3.83M)(2.83M)(8.36M)(8.3M)
Acquisitions (Net)000278.65M0
Purchases of Investments00(94.9M)0(140.93M)
Sales of Investments00117.96M0179M
Other Investing Activities1.32M(84.3M)092.88M(5M)
Investing Cash Flow(11.95M)(88.13M)20.24M363.17M24.77M
Debt Repayment9.5M18.16M(2.08M)(63.19M)0
Common Stock Issued00001.05M
Common Stock Repurchased(1.79M)(774K)(5.41M)(40.95M)0
Dividends Paid00000
Other Financing Activities8.25M213.37M827K1.53M(484K)
Financing Cash Flow15.96M230.76M(6.81M)(102.62M)570K
Effect of Forex Changes(21K)(404K)34K(785K)842K
Net Change in Cash(40.07M)52.86M(29.83M)116.32M(48.17M)
Free Cash Flow(57.33M)(93.2M)(46.12M)(151.81M)(82.65M)

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.